{{noteTA|G1 = ME}} {{Medical}} 
{{drugbox
| verifiedrevid = 395152746
| IUPAC_name = (11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
|synonyms = <small>11,17-dihydroxy-17- (2-hydroxyacetyl)- 10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17- dodecahydrocyclopenta [a]phenanthren-3-one</small>
| image = Prednisolone-2D-skeletal.svg
| image2 = Prednisolone-3D-balls.png
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9PHQ9Y1OLM
| InChI1 = 1/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
| InChIKey1 = OIGNJSKKLXVSLS-VWUMJDOOBF
| smiles = O=C\1\C=C/[C@]4(/C(=C/1)CC[C@@H]2[C@@H]4[C@@H](O)C[C@@]3([C@@](O)(C(=O)CO)CC[C@@H]23)C)C
| CAS_number = 50-24-8
| CAS_number_Ref = {{cascite|correct|CAS}}
| ChemSpiderID = 5552
| ATC_prefix = A07
| ATC_suffix = EA01
| ATC_supplemental = {{ATC|C05|AA04}}, {{ATC|D07|AA03}}, {{ATC|D07|XA02}}, {{ATC|H02|AB06}}, {{ATC|R01|AD02}}, {{ATC|S01|BA04}}, {{ATC|S01|CB02}}, {{ATC|S02|BA03}}, {{ATC|S03|BA02}}
| PubChem = 5755
| IUPHAR_ligand = 2866
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00860
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00472
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 8378
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 131
| C=21 | H=28 | O=5
| molecular_weight = 360.444 g/mol
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 2-3 小時
| excretion = 潑尼松發經由尿液排泄
| pregnancy_AU = A
| pregnancy_US = C
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = 
}}

<!-- Definition and medical uses -->
'''潑尼松龍'''（{{lang-en|Prednisolone}}），是一種[[皮質類固醇|皮質類固醇]]，用以治療特定種類的[[過敏|過敏]]、[[炎症|炎症]]、[[自體免疫性疾病|自體免疫性疾病]]及[[癌症|癌症]]<ref name=WHO2008>{{cite book | title = WHO Model Formulary 2008 | year = 2009 | isbn = 9789241547659 | vauthors = ((World Health Organization)) | veditors = Stuart MC, Kouimtzi M, Hill SR | hdl = 10665/44053 | author-link = World Health Organization | publisher = World Health Organization |pages=53–54 }}</ref><ref name=AHFS2016>{{cite web|title=Prednisolone|url=https://www.drugs.com/monograph/prednisolone.html|publisher=The American Society of Health-System Pharmacists|access-date=8 December 2016|url-status=live|archive-url=https://web.archive.org/web/20161223131831/https://www.drugs.com/monograph/prednisolone.html|archive-date=23 December 2016}}</ref>。可治療病症如{{le|腎上腺機能不全|adrenocortical insufficiency}}、[[高血鈣|高血鈣]]、[[類風濕性關節炎|類風濕性關節炎]]、[[皮膚炎|皮膚炎]]、眼睛發炎、[[哮喘|哮喘]]以及[[多發性硬化症|多發性硬化症]]<ref name=AHFS2016/>。本品可口服和[[靜脈注射|靜脈注射]]，或作成皮膚乳膏和[[眼藥水|眼藥水]]使用<ref name=AHFS2016/><ref name="Orapred ODT label">{{cite web | title=Orapred ODT- prednisolone sodium phosphate tablet, orally disintegrating | website=DailyMed | date=11 September 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e379543-c4cf-4e72-953b-db15b7f0c2a1 | access-date=9 March 2020 | archive-date=2020-08-17 | archive-url=https://web.archive.org/web/20200817120735/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e379543-c4cf-4e72-953b-db15b7f0c2a1 | dead-url=no }}</ref><ref name="Omnipred label">{{cite web | title=Omnipred- prednisolone acetate suspension | website=DailyMed | date=9 September 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bbb4356-b4b3-4497-a3a3-8f4b65d326fe | access-date=9 March 2020 | archive-date=2020-03-09 | archive-url=https://web.archive.org/web/20200309183950/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bbb4356-b4b3-4497-a3a3-8f4b65d326fe | dead-url=no }}</ref>。
<!--'''潑尼松龍'''（{{lang-en|'''Prednisolone'''}}），又譯作'''康速龍錠'''（{{lang-en|Donison}}），是[[皮質類固醇|皮質類固醇]]藥物<ref name=miaoli>{{cite web |url=http://web.mil.doh.gov.tw/drug/file/P/Prednisone.pdf |title=Prednisolone用藥指導單張 |language=zh-hant |publisher=[[苗栗醫院|苗栗醫院]] |accessdate=2012-02-28 |deadurl=yes |archiveurl=https://web.archive.org/web/20120417024820/http://web.mil.doh.gov.tw/drug/file/P/Prednisone.pdf |archivedate=2012-04-17 }}</ref>，用於治療某些類型的[[過敏|過敏]]、[[炎症|炎症]]、[[自體免疫性疾病|自體免疫性疾病]]及[[癌症|癌症]]<ref name=WHO2008>{{cite book|title=WHO Model Formulary 2008|date=2009|publisher=World Health Organization|isbn=9789241547659|pages=53–54|url=http://apps.who.int/medicinedocs/documents/s16879e/s16879e.pdf|access-date=8 December 2016|dead-url=no|archive-url=https://web.archive.org/web/20161213060118/http://apps.who.int/medicinedocs/documents/s16879e/s16879e.pdf|archive-date=13 December 2016}}</ref><ref name=AHFS2016/>。它可透過口腔、[[靜脈注射|靜脈注射]]作為乳膏和[[眼藥水|眼藥水]]使用<ref>{{cite web|title=Search results – (eMC)|url=https://www.medicines.org.uk/emc/search/?q=Prednisolone&a=330,2470,969,739|website=www.medicines.org.uk|access-date=13 December 2016|dead-url=no|archive-url=https://web.archive.org/web/20161220175326/https://www.medicines.org.uk/emc/search/?q=Prednisolone&a=330,2470,969,739|archive-date=20 December 2016}}</ref>。治療的疾病包括有：{{le|腎上腺皮質功能不全|Adrenal insufficiency}}、[[高血鈣|高血鈣]]、[[類風濕性關節炎|類風濕性關節炎]]、[[皮膚炎|皮膚炎]]、眼睛發炎、[[哮喘|哮喘]]<ref>Fiel SB, Vincken W. Systemic corticosteroid therapy for acute asthma exacerbations. J Asthma. 2006 Jun-Jul;43(5):321-31. Review. PMID 16801135</ref>，及[[多發性硬化症|多發性硬化症]]<ref name=AHFS2016/><ref>Thrower BW. Relapse management in multiple sclerosis. Neurologist. 2009 Jan;15(1):1-5. Review. PMID 19131851</ref>。-->

<!-- Side effects and mechanism -->
短期使用潑尼松龍的副作用為噁心和疲倦<ref name=WHO2008/>，更嚴重的副作用則為引發精神病相關問題，100人中約有5％ 的人會發生<ref name=ER2014>{{cite web|title=Pevanti 10mg Tablets – Summary of Product Characteristics (SPC) – (eMC)|url=https://www.medicines.org.uk/emc/medicine/30014|date=1 December 2014|website=www.medicines.org.uk|access-date=13 December 2016|url-status=live|archive-url=https://web.archive.org/web/20161220175357/https://www.medicines.org.uk/emc/medicine/30014|archive-date=20 December 2016}}</ref>。長期使用的常見副作用則有[[骨質疏鬆症|骨質疏鬆症]]、虛弱無力、[[念珠菌症|念珠菌症]]，及容易出現瘀傷<ref name=AHFS2016/>。雖然在[[妊娠|懷孕]]後期，短期使用是安全的，然而在懷孕初期使用，或在後期長期使用，有可能會傷害到嬰兒<ref name="Drugs.com pregnancy">{{cite web | title=Prednisolone Use During Pregnancy | website=Drugs.com | date=16 January 2000 | url=https://www.drugs.com/pregnancy/prednisolone.html | access-date=9 March 2020 | archive-date=2016-12-21 | archive-url=https://web.archive.org/web/20161221002545/https://www.drugs.com/pregnancy/prednisolone.html | dead-url=no }}</ref>。潑尼松龍係為[[氫羥腎上腺皮質素|氫羥腎上腺皮質素]]（氫化可體松）製成的[[糖皮質素|糖皮質素]]<ref name=Kim2016>{{cite book |last1=Kim |first1=Kyu-Won |last2=Roh |first2=Jae Kyung |last3=Wee |first3=Hee-Jun |last4=Kim |first4=Chan  |title=Cancer Drug Discovery: Science and History |date=2016 |publisher=Springer |isbn=9789402408447 |page=169 |url=https://books.google.com/books?id=BR9_DQAAQBAJ&pg=PA169 |url-status=live|archive-url= https://web.archive.org/web/20170910174620/https://books.google.com/books?id=BR9_DQAAQBAJ&pg=PA169 |archive-date=2017-09-10 }}</ref>。
<!--短期使用潑尼松龍的副作用包括噁心和疲倦<ref name=WHO2008/>。更嚴重的副作用包括精神病的問題，這可能發生於大約5％的人身上<ref name=ER2014>{{cite web|title=Pevanti 10mg Tablets – Summary of Product Characteristics (SPC) – (eMC)|url=https://www.medicines.org.uk/emc/medicine/30014|date=1 December 2014|website=www.medicines.org.uk|access-date=13 December 2016|dead-url=no|archive-url=https://web.archive.org/web/20161220175357/https://www.medicines.org.uk/emc/medicine/30014|archive-date=20 December 2016}}</ref>。長期使用的常見副作用包括[[骨質疏鬆症|骨質疏鬆症]]、軟弱無力、[[念珠菌症|念珠菌症]]，以及容易出現瘀傷<ref name=AHFS2016/>。雖然在懷孕後期作短期使用是安全的，然而在懷孕初期或長期使用有時會對嬰兒損害產生關聯<ref>{{cite web|title=Prednisolone Use During Pregnancy {{!}} Drugs.com|url=https://www.drugs.com/pregnancy/prednisolone.html|website=www.drugs.com|access-date=13 December 2016|dead-url=no|archive-url=https://web.archive.org/web/20161221002545/https://www.drugs.com/pregnancy/prednisolone.html|archive-date=21 December 2016}}</ref>。-->

<!-- History and culture -->
潑尼松龍發現於1955年，同年核可為藥物之用<ref name=Kim2016/>。本品名列[[世界衛生組織基本藥物標準清單|世界衛生組織基本藥物標準清單]]中<ref name="WHO21st">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }}</ref>，現在已有[[通用名藥物|學名藥]]流通<ref name=AHFS2016/>。2017年，在[[美國|美國]]最常用的處方籤藥物清單中，潑尼松龍排名第129，該年開出至少500萬劑<ref>{{cite web | title = The Top 300 of 2021 | url = https://clincalc.com/DrugStats/Top300Drugs.aspx | website = ClinCalc | access-date = 18 February 2021 | archive-date = 2017-03-16 | archive-url = https://web.archive.org/web/20170316102646/https://clincalc.com/DrugStats/Top300Drugs.aspx | dead-url = no }}</ref><ref>{{cite web | title = Prednisolone - Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Prednisolone | access-date = 18 February 2021 | archive-date = 2020-04-12 | archive-url = https://web.archive.org/web/20200412043737/https://clincalc.com/DrugStats/Drugs/Prednisolone | dead-url = no }}</ref>。
<!--潑尼松龍是由[[氫羥腎上腺皮質素|氫羥腎上腺皮質素]]製成的[[糖皮质激素|糖皮質激素]]，於1955年被發現並獲准用於醫療用途<ref name=Kim2016>{{cite book |last1=Kim |first1=Kyu-Won |last2=Roh |first2=Jae Kyung |last3=Wee |first3=Hee-Jun |last4=Kim |first4=Chan | name-list-format = vanc |title=Cancer Drug Discovery: Science and History |date=2016 |publisher=Springer |isbn=9789402408447 |page=169 |url=https://books.google.com/books?id=BR9_DQAAQBAJ&pg=PA169 |dead-url=no|archive-url= https://web.archive.org/web/20170910174620/https://books.google.com/books?id=BR9_DQAAQBAJ&pg=PA169 |archive-date=2017-09-10 }}</ref>，它也是[[潑尼松|潑尼松]]的一種[[活性代謝產物|活性代謝產物]]<ref name="Davis">{{cite journal| author = Davis M, Williams R, Chakraborty J, ''et al.''| title = Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability| url = https://archive.org/details/sim_british-journal-of-clinical-pharmacology_1978-06_5_6/page/501| journal = British Journal of Clinical Pharmacology| volume = 5| issue = 6| pages = 501–5| pmid = 656293| pmc = 1429358|date=June 1978}}</ref>，同時亦作為藥物使用。它主要對[[糖皮質激素|糖皮質激素]]活躍，礦物類皮質激素活性低，使其適用於廣泛的[[炎症|炎症]]及[[自體免疫|自體免疫]]狀況<ref name=Pharmacokinet>Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. Review. PMID 15634032</ref>，它也被用於治療[[類肉瘤病|類肉瘤病]]<ref>{{cite web |url=http://blog.udn.com/jnwu/3302280 |title=類肉瘤病 Sarcoidosis |date=2009-09-09 |accessdate=2012-02-28 |language=zh-hant}}</ref>，但機制不明。
它在[[世界衛生組織基本藥物標準清單|世界衛生組織基本藥物標準清單]]中，是[[醫療系統|醫療系統]]中所需的最有效、最安全的藥物<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1 |publisher=World Health Organization |access-date=8 December 2016|date=April 2015|dead-url=no|archive-url=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archive-date=13 December 2016}}</ref>。它可以作為通用藥物的使用<ref name=AHFS2016>{{cite web|title=Prednisolone|url=https://www.drugs.com/monograph/prednisolone.html|publisher=The American Society of Health-System Pharmacists|access-date=8 December 2016|dead-url=no|archive-url=https://web.archive.org/web/20161223131831/https://www.drugs.com/monograph/prednisolone.html|archive-date=23 December 2016}}</ref>。在發展中國家，每5毫克片劑的價格約$0.01美元<ref name=ERC2014>{{cite web|title=Prednisolone|url=http://apps.who.int/medicinedocs/documents/s21982en/s21982en.pdf|website=WHO International Drug Price Indicator Guide, 2014|accessdate=2019-10-21|archive-date=2017-01-10|archive-url=https://web.archive.org/web/20170110144554/http://apps.who.int/medicinedocs/documents/s21982en/s21982en.pdf|dead-url=no}}</ref>。在2017年，500萬種處方藥物中，它是第136個美國最常處方的藥物<ref>{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=clincalc.com |accessdate=22 December 2018 |archive-date=2019-06-28 |archive-url=https://web.archive.org/web/20190628132617/https://clincalc.com/DrugStats/Top300Drugs.aspx |dead-url=no }}</ref>。-->

== 醫療用途 ==
潑尼松龍是一種以[[糖皮質激素|糖皮質激素]]為主的[[皮質類固醇|皮質類固醇]]藥物，其[[鹽皮質激素|鹽皮質激素]]活性低，使其可用於治療多種範圍廣泛的炎症和自體免疫疾病<ref>{{cite journal | vauthors = Czock D, Keller F, Rasche FM, Häussler U | title = Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids | journal = Clinical Pharmacokinetics | volume = 44 | issue = 1 | pages = 61–98 | year = 2005 | pmid = 15634032 | doi = 10.2165/00003088-200544010-00003 }}</ref>，例如：[[哮喘|哮喘]]<ref>{{cite journal | vauthors = Fiel SB, Vincken W | title = Systemic corticosteroid therapy for acute asthma exacerbations | journal = The Journal of Asthma | volume = 43 | issue = 5 | pages = 321–31 | date = Jun 2006 | pmid = 16801135 | doi = 10.1080/02770900600567163 }}</ref>、[[葡萄膜炎|葡萄膜炎]]、{{le|壞疽性膿皮病|Pyoderma gangrenosum}}、[[類風濕關節炎|類風濕關節炎]]、[[蕁麻疹|蕁麻疹]]<ref name="Angie">{{cite journal | vauthors = Spickett G |title=Urticaria and angioedema |journal=J R Coll Physicians Edinb |date=2014 |volume=44 |issue=1 |pages=50–4 | doi = 10.4997/JRCPE.2014.112|pmid=24995449 }}</ref>、[[血管性水腫|血管性水腫]]<ref name="Angie"/>、[[潰瘍性結腸炎|潰瘍性結腸炎]]、[[心包炎|心包炎]]、{{le|顳動脈炎|Giant-cell arteritis}}及[[克隆氏症|克隆氏症]]、[[貝爾氏麻痹症|貝爾氏麻痹症]]、[[多發性硬化症|多發性硬化症]]<ref>{{cite journal | vauthors = Thrower BW | title = Relapse management in multiple sclerosis | journal = The Neurologist | volume = 15 | issue = 1 | pages = 1–5 | date = January 2009 | pmid = 19131851 | doi = 10.1097/NRL.0b013e31817acf1a }}</ref>、[[叢集性頭痛|叢集性頭痛]]、[[血管炎|血管炎]]、[[急性淋巴性白血病|急性淋巴性白血病]]及{{le|自體免疫性肝炎|Autoimmune hepatitis}}<ref>{{cite journal | vauthors = Lambrou GI, Vlahopoulos S, Papathanasiou C, Papanikolaou M, Karpusas M, Zoumakis E, Tzortzatou-Stathopoulou F | title = Prednisolone exerts late mitogenic and biphasic effects on resistant acute lymphoblastic leukemia cells: Relation to early gene expression | journal = Leukemia Research | volume = 33 | issue = 12 | pages = 1684–95 | date = December 2009 | pmid = 19450877 | doi = 10.1016/j.leukres.2009.04.018 }}</ref>、[[全身性紅斑狼瘡|全身性紅斑狼瘡]]、[[川崎氏病|川崎氏病]]<ref>{{cite journal | vauthors = Miura M, Tamame T, Naganuma T, Chinen S, Matsuoka M, Ohki H | title = Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy | journal = Paediatrics & Child Health | volume = 16 | issue = 8 | pages = 479–84 | date = October 2011 | pmid = 23024586 | pmc = 3202387 | doi = 10.1093/pch/16.8.479 }}</ref>、[[皮肌炎|皮肌炎]]<ref name="Cima Labs Inc 2006">Product Information: ORAPRED ODT(TM) orally disintegrating tablets, prednisolone sodium phosphate orally disintegrating tablets. Cima Labs Inc, Alpharetta, GA, 2006.</ref>和[[結節病|結節病]]<ref>{{cite journal | vauthors = Gera K, Gupta N, Ahuja A, Shah A | title = Acute alveolar sarcoidosis presenting with hypoxaemic respiratory failure | journal = BMJ Case Reports | volume = 2014 | pages = bcr2013202247 | date = April 2014 | pmid = 24789154 | pmc = 4024548 | doi = 10.1136/bcr-2013-202247 }}</ref>。

潑尼松龍滴眼液是一種腎上腺皮質類固醇產品，製成無菌眼科懸液，並用於減輕影響眼睛的腫脹、發紅、痕癢和[[過敏|過敏]]反應<ref>{{Cite web|url =http://www.allergan.com/assets/pdf/pred_forte_pi.pdf|title =Pred Forte Package Insert|dead-url =no|archive-url =https://web.archive.org/web/20160304095704/http://www.allergan.com/assets/pdf/pred_forte_pi.pdf|archive-date =2016-03-04}}</ref><ref>Product Information: OMNIPRED(TM) ophthalmic suspension, prednisolone acetate ophthalmic suspension. Alcon Laboratories Inc, Fort Worth, TX, 2005</ref>。它已開展探索作為治療[[角膜炎|角膜炎]]的選項<ref name="Herretes">{{cite journal | vauthors = Herretes S, Wang X, Reyes JM | title = Topical corticosteroids as adjunctive therapy for bacterial keratitis | journal = The Cochrane Database of Systematic Reviews | volume =  | issue = 10 | pages = CD005430 | date = October 2014 | pmid = 25321340 | pmc = 4269217 | doi = 10.1002/14651858.CD005430.pub3 }}</ref>。潑尼松龍也可用於治療從季節性過敏至[[藥物過敏|藥物過敏]]的過敏反應<ref name=":0">{{Cite web|url = http://www.laserpharmaceuticals.com/mydocuments/millipred_os_package_insert.pdf.|title = Millipred tablets package insert|date = |access-date = |website = }}{{Dead link}}</ref>。

潑尼松龍也可用於[[器官移植|器官移植]]的[[免疫抑制|免疫抑制]]藥物<ref name="Cima Labs Inc 2006"/><ref>{{cite journal | vauthors = Vethe NT, Midtvedt K, Asberg A, Amundsen R, Bergan S | title = [Drug interactions and immunosuppression in organ transplant recipients] | journal = Tidsskrift for den Norske Laegeforening | volume = 131 | issue = 20 | pages = 2000–3 | date = October 2011 | pmid = 22016125 | doi = 10.4045/tidsskr.11.0138 }}</ref>。

低劑量的潑尼松龍可用作治療原發性腎上腺功能不全（[[愛迪生氏病|愛迪生氏病]]）<ref>{{cite journal | vauthors = Husebye ES, Allolio B, Arlt W, Badenhoop K, Bensing S, Betterle C, Falorni A, Gan EH, Hulting AL, Kasperlik-Zaluska A, Kämpe O, Løvås K, Meyer G, Pearce SH | title = Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency | journal = Journal of Internal Medicine | volume = 275 | issue = 2 | pages = 104–15 | date = February 2014 | pmid = 24330030 | doi = 10.1111/joim.12162 }}</ref><ref>{{cite book | title = AMA Department of Drugs: AMA Drug Evaluations | url = https://archive.org/details/sim_jama_1987_258_index | edition = 6th | publisher = American Medical Association | location = Chicago, IL | date = 1986 }}</ref>。

皮質類固醇可抑制多種誘因的炎症反應，據推測療效是會延遲或緩慢的<ref>{{cite journal | vauthors = Schwiebert LM, Beck LA, Stellato C, Bickel CA, Bochner BS, Schleimer RP, Schwiebert LA | title = Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions | journal = The Journal of Allergy and Clinical Immunology | volume = 97 | issue = 1 Pt 2 | pages = 143–52 | date = January 1996 | pmid = 8568145 | doi = 10.1016/s0091-6749(96)80214-4 }}</ref>。它們能抑制水腫、纖維蛋白沉積、毛細血管擴張、[[白細胞|白細胞]]遷移、毛細血管增生、成纖維細胞增生、[[膠原蛋白|膠原蛋白]]沉積、以疤痕形成的發炎<ref>{{cite journal | vauthors = Lee SH | title = Mechanisms of Glucocorticoid Action in Chronic Rhinosinusitis | journal = Allergy, Asthma & Immunology Research | volume = 7 | issue = 6 | pages = 534–7 | date = November 2015 | pmid = 26333699 | pmc = 4605925 | doi = 10.4168/aair.2015.7.6.534 }}</ref>。

== 副作用 ==
潑尼松龍的使用會帶來一些不良反應：
* 食慾增加，體重增加、噁心和[[不適|不適]]；
* 感染風險增加；
* 兒童的[[心血管疾病|心血管疾病]]事件；
* 皮膚病學的反應包括臉紅、青腫／皮膚變色、傷口癒合不良、皮膚變薄、皮疹、積液積聚、和異常的毛髮生長；
* [[高血糖|高血糖]]，糖尿病患者可能需要增加[[胰島素|胰島素]]或糖尿病治療；
* 月經異常；
* 對激素的反應較弱，尤其是在手術或疾病等壓力大的情況下；
* 電解質變化：[[血壓|血壓]]升高、鈉增加和低鉀，導致{{le|鹼中毒|Alkalosis}}；
* 胃腸道系統的影響：胃壁腫脹、肝酶的可逆性增加和胃潰瘍的風險；
* 肌肉和骨骼異常，例如肌肉無力／肌肉流失、[[骨質疏鬆症|骨質疏鬆症]]、長骨骨折、肌腱斷裂和背部骨折。
* 神經系統影響，包括非自主運動（[[驚厥|抽搐]]）、頭痛及[[眩暈_(醫學)|眩暈]]；
* 行為障礙<ref name=":2" />

鼻中隔穿孔及和腸穿孔也是明顯的副作用，在某些病理情況下會限制類固醇的使用<ref>{{cite journal | vauthors = ReMine SG, McIlrath DC | title = Bowel perforation in steroid-treated patients | url = https://archive.org/details/sim_annals-of-surgery_1980-10_192_4/page/581 | journal = Annals of Surgery | volume = 192 | issue = 4 | pages = 581–6 | year = 1980 | pmid = 7425698 | pmc = 1347010 | doi = 10.1097/00000658-198010000-00016 }}</ref><ref>{{cite journal | vauthors = Cervin A, Andersson M | title = Intranasal steroids and septum perforation--an overlooked complication? A description of the course of events and a discussion of the causes | journal = Rhinology | volume = 36 | issue = 3 | pages = 128–32 | date = September 1998 | pmid = 9830677 }}</ref>。

在退出長期或大劑量使用潑尼松龍後，可能導致{{le|腎上腺功能不全|Adrenal insufficiency}}<ref name=":2" />；

=== 懷孕與餵哺母乳 ===
儘管尚未有關於潑尼松龍在孕婦中使用的主要人體研究，對幾種動物的研究顯示它可能導致先天缺陷，例如增加[[唇顎裂|唇顎裂]]的機會。當利益大於風險時，潑尼松龍應在孕婦身上使用，而母親懷孕期間使用潑尼松龍時，所產下的孩子應該受到腎上腺功能受損的監控。

在服用潑尼松龍的母親的母乳中發現有潑尼松龍<ref name=":2">{{Cite web|url =http://products.sanofi.ca/en/pediapred.pdf|title =PEDIAPRED|dead-url =no|archive-url =https://web.archive.org/web/20160304223644/http://products.sanofi.ca/en/pediapred.pdf|archive-date =2016-03-04}}</ref>。

== 藥理學 ==
作為糖皮質激素，潑尼松龍的親脂性結構使其易於通過細胞膜，然後結合其位於細胞質中的各自的糖皮質激素受體（GCR）。結合後，GC／GCR複合物的形成導致[[分子伴侶|分子伴侶]]從糖皮質激素受體的解離，使GC／GCR複合物在核內移位。此過程在結合後20分鐘內發生。一旦進入細胞核，[[蛋白二聚體|蛋白二聚體]]GC/GCR複合物結合到稱為糖皮質激素反應元件（GREs）的特定DNA結合，從而導致基因表達或抑制。正反應元件（GREs）與負反應元件（GREs）的結合會導致抗炎蛋白的合成，這會阻斷炎症基因的[[轉錄|轉錄]]<ref>{{cite journal | vauthors = Stahn C, Löwenberg M, Hommes DW, Buttgereit F | title = Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists | journal = Molecular and Cellular Endocrinology | volume = 275 | issue = 1–2 | pages = 71–8 | date = September 2007 | pmid = 17630118 | doi = 10.1016/j.mce.2007.05.019 | url = https://hal.archives-ouvertes.fr/hal-00531935/file/PEER_stage2_10.1016%252Fj.mce.2007.05.019.pdf | access-date = 2019-10-21 | archive-date = 2020-09-28 | archive-url = https://web.archive.org/web/20200928224448/https://hal.archives-ouvertes.fr/hal-00531935/file/PEER_stage2_10.1016%252Fj.mce.2007.05.019.pdf | dead-url = no }}</ref>。

== 化學 ==
潑尼松龍是一種[[孕烷|孕烷]][[有機化合物|有機化合物]]的[[皮質類固醇|皮質類固醇]]，它與其同源的[[強的松|強的松]]密切相關，兩者具有相同結構的化合物，除了在C<sub>11</sub>附近節省了兩個氫分子。它也被稱為δ1-皮質醇、δ1-氫化強的松、脫氫皮質醇1號及2號、脫氫皮質醇1號及2號、或脫氧皮質醇1號及2號<ref name="Elks2014">{{cite book | vauthors = Elks J |title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies |url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1011 |date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=1011–1012|dead-url=no|archive-url=https://web.archive.org/web/20170910174620/https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1011|archive-date=10 September 2017}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA869|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=869–|dead-url=no|archive-url=https://web.archive.org/web/20170910174620/https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA869|archive-date=2017-09-10}}</ref>。

== 社會與文化 ==
=== 運動員禁用 ===
作為一種糖皮質激素，根據[[世界反興奮劑組織|世界反興奮劑組織]]（WADA）的反興奮劑規定，未經授權或在比賽中途透過口服、靜脈注射、肌肉注射或以直腸途徑臨時使用潑尼松龍都是被禁止的<ref name=":1">{{Cite web |title=The 2011 Prohibited List |url=http://www.wada-ama.org/en/World-Anti-Doping-Program/Sports-and-Anti-Doping-Organizations/International-Standards/Prohibited-List/The-2011-Prohibited-List/Prohibited-In-Competition/ |dead-url=no |archive-url=https://web.archive.org/web/20110808210916/http://www.wada-ama.org/en/World-Anti-Doping-Program/Sports-and-Anti-Doping-Organizations/International-Standards/Prohibited-List/The-2011-Prohibited-List/Prohibited-In-Competition/ |archive-date=2011-08-08 }}</ref><ref>{{Cite web |title=The 2008 Prohibited List}}{{cite web |url=http://www.wada-ama.org/rtecontent/document/2008_List_En.pdf |title=存档副本 |accessdate=2007-10-30 |deadurl=yes |archiveurl=https://web.archive.org/web/20071030051804/http://www.wada-ama.org/rtecontent/document/2008_List_En.pdf |archivedate=2007-10-30 }}</ref>。符合WADA規定的話，該藥物可與TUE（治療用途豁免）於比賽中使用。在比賽中局部使用潑尼松龍，以及在比賽以外的任何用途則不受規範<ref name=":1" />。根據《奇幻熊》網站在2016年10月3日公佈的最新一份解密指，[[日本|日本]][[乒乓球|乒乓球]][[運動員|運動員]][[福原愛|福原愛]]於2016年5月18日至6月17日的比賽期間曾在[[國際乒聯|國際乒聯]]的許可下獲得了該藥物的「治療用藥豁免權」。

== 獸醫用途 ==
潑尼松龍也可用於治療貓、狗及雪貂的炎症和過敏性疾病的治療。

== 藥劑名稱 ==
* 「柏理」康速龍錠，5毫克，（陪尼皮質醇），臺灣"應元化學製藥公司"（柏理公司委托）。Compesolon Tablets 5mg "Pine Lawer" (Prednisolone).

==參考文獻==
{{Reflist}}

==外部連結==
*[http://www.chimei.org.tw/main/right/right01/cmh_department/55500/guide/08.prednisolone.pdf Prednisolone 樂爾爽片®]{{dead link|date=2018年3月 |bot=InternetArchiveBot |fix-attempted=yes }}

{{血管保护药}}
{{Otologicals}}

[[Category:艾伯維品牌|Category:艾伯維品牌]]
[[Category:鹽皮質激素|Category:鹽皮質激素]]
[[Category:糖皮质激素|Category:糖皮质激素]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]
[[Category:耳科用药|Category:耳科用药]]